For this reason, the Japan Lung Cancer Society guidelines for lung cancer treatment recommend osimertinib for use as the primary treatment for patients with advanced nonsmall cell lung cancer, with performance status 0-1 and common mutations of the EGFR gene. Here, EGFR is linked to lung carcinoma.